Camizestrant (SERD) in HR+/HER2- Advanced Breast Cancer: SERENA-2 Trial

On October 26, 2022, AstraZeneca announced the positive results of the SERENA-2 Phase 2 clinical trial, evaluating Camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), in patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer.

Study Design: SERENA-2 Trial

The SERENA-2 trial is a randomized, open-label, multi-dose Phase 2 study. It compared different doses of Camizestrant (75 mg or 150 mg) against the current standard-of-care SERD, Faslodex (Fulvestrant, 500 mg), in patients who had previously received at least one line of endocrine therapy for advanced disease.

The primary endpoint was progression-free survival (PFS).

Key Results

The trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in PFS for patients receiving Camizestrant compared to those receiving Fulvestrant:

• Superior Efficacy: Both the 75 mg and 150 mg doses of Camizestrant reduced the risk of disease progression or death.
• Safety Profile: Camizestrant was well-tolerated, with a safety profile consistent with previous studies. No new safety signals were identified.

Conclusion

Dr. Mafalda Oliveira from the Vall d'Hebron Institute of Oncology stated that the SERENA-2 results provide strong evidence for the potential of Camizestrant as a new treatment option. By outperforming Fulvestrant—a standard therapy for over 20 years—Camizestrant demonstrates the importance of next-generation SERDs in addressing the needs of patients with HR+ advanced breast cancer.

Source: AstraZeneca Press Release - SERENA-2 Results

#BreastCancer #Camizestrant #SERD #HRPositive #Faslodex #CancerResearch #SERENA2

Figure 1

Figure 2

Figure 3

Figure 4